Collaboration to Develop Sepsis Diagnostics

A joint agreement for the evaluation and potential commercialization of sepsis markers has been announced by SIRS-Lab GmbH (Jena, Germany) and Biosite Inc. (San Diego, CA, USA). Financial terms were not disclosed.

Under the agreement, SIRS-Lab will provide access to selected biomarkers for sepsis. Biosite will make antibodies to those selected targets, using its proprietary antibody-
development process. This process combines the immunization of mice and phage display to generate highly diverse libraries of antibodies with high affinity and low cross-reactivity, called Omniclonal antibodies. These antibodies will then be used to generate assays for the measurement of the selected biomarker targets in blood samples. Validated biomarkers will be assessed for their commercial potential, with high-value markers being added to Biosite's product-development process.

"This agreement combines the strengths of both companies: Biosite's proven antibody development and commercialization process for diagnostic products with our expertise in molecular medicine concerning inflammatory diseases,” noted Dr. Stefan Rubwurm, CEO of SIRS-Lab.

SIRS-Lab is a research-driven diagnostics company focused on the identification and development of biomarkers for the development of diagnostic systems that can identify inflammatory-immunologic host responses or bacterial causes of infection. Biosite commercializes proteomics discoveries that advance medical diagnosis. The company's Triage diagnostics are used in more than 50 international markets.





Related Links:
SIRS-Lab
Biosite